- Home
- RENB vs IVVD Comparison
RENB vs IVVD Comparison
Compare RENB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- IVVD
- Stock Information
- Founded
- RENB 2011
- IVVD 2020
- Country
- RENB United States
- IVVD United States
- Employees
- RENB N/A
- IVVD N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- IVVD Health Care
- Exchange
- RENB Nasdaq
- IVVD Nasdaq
- Market Cap
- RENB 57.7M
- IVVD 63.4M
- IPO Year
- RENB N/A
- IVVD 2021
- Fundamental
- Price
- RENB $0.17
- IVVD $1.18
- Analyst Decision
- RENB
- IVVD Strong Buy
- Analyst Count
- RENB 0
- IVVD 4
- Target Price
- RENB N/A
- IVVD $3.64
- AVG Volume (30 Days)
- RENB 993.7K
- IVVD 15.0M
- Earning Date
- RENB 11-13-2025
- IVVD 11-13-2025
- Dividend Yield
- RENB N/A
- IVVD N/A
- EPS Growth
- RENB N/A
- IVVD N/A
- EPS
- RENB N/A
- IVVD N/A
- Revenue
- RENB N/A
- IVVD $46,210,000.00
- Revenue This Year
- RENB N/A
- IVVD $385.94
- Revenue Next Year
- RENB N/A
- IVVD $62.62
- P/E Ratio
- RENB N/A
- IVVD N/A
- Revenue Growth
- RENB N/A
- IVVD 1941.08
- 52 Week Low
- RENB $0.17
- IVVD $0.35
- 52 Week High
- RENB $2.10
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- RENB 31.45
- IVVD 57.40
- Support Level
- RENB $0.18
- IVVD $1.05
- Resistance Level
- RENB $0.22
- IVVD $1.45
- Average True Range (ATR)
- RENB 0.02
- IVVD 0.16
- MACD
- RENB -0.00
- IVVD 0.02
- Stochastic Oscillator
- RENB 0.53
- IVVD 51.75
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.